Secondary goals include safety, evaluation and pharmacokinetics of biomarkers. Cristina Pleased, CEO of BioInvent, commented: ‘BI-505 is definitely one of these of BioInvent's capacity to initiate in-home clinical projects, predicated on our own F.We.R.S. The 1st clinical research of BI-505 attained our goals. The candidate medication was well indicated and tolerated therapeutic impact, since seven of a complete of 29 sufferers with advanced multiple myeloma demonstrated steady disease for at least 8 weeks. The beginning of this stage II research is another essential step of progress for BI-505 and we think that BI-505 gets the potential to address a significant unmet want in a wide population of patients.’..Financing for the scholarly research originated from the VA, and from the Michigan Diabetes Training and Analysis Center. Reference: Annals of Internal Medication, Might 20, 2008, Vol. 148, No. 10.. Blue Blue and Cross Shield of Texas continues to aid TCQPS to review and improve patient security The Texas Middle for Quality & Patient Security announced today that Blue Cross and Blue Shield of Texas is continuing its support for the TCQPS with a $150,000 donation to review and improve patient safety, including reduced amount of hospital readmissions and hospital-acquired infections. TCQPS started this year 2010 as an initiative of the Texas Medical center Association Foundation to supply support, tools and assets that improve patient security and quality of treatment through collaboration with condition and national experts along with other crucial stakeholders.